18
Participants
Start Date
December 24, 2018
Primary Completion Date
August 11, 2022
Study Completion Date
March 1, 2024
RRx-001 + eLOOP Device
RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
Cisplatin/carboplatin plus etoposide
Standard of care platinum doublet chemotherapy
University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center, Baltimore
Mid Florida Hematology and Oncology Center, Orange City
AdventHealth Hematology and Oncology, Orlando
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa
Tennessee Cancer Specialists, Knoxville
University of Mississippi Medical Center, Jackson
Norton Cancer Institute, Norton Healthcare Pavilion, Louisville
Rush University Medical Center, Chicago
Washington University School of Medicine - Siteman Cancer Center, St Louis
The University of Kansas Cancer Center, Westwood
Cotton O'Neil Clinical Research Center.Hematology & Oncology, Topeka
Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha
Stephenson Cancer Center, Oklahoma City
HOPE Cancer Center of East Texas, Tyler
Millennium Oncology, Houston
Centura Health Research Center, Denver
Utah Cancer Specialist, Salt Lake City
Dartmouth-Hitchcock Medical Center, Lebanon
Lead Sponsor
EpicentRx, Inc.
INDUSTRY